This is an open-label, multicenter, single-arm, expanded access study designed t o provide alectinib to patients with anaplastic lymphoma kinase-rearranged (ALK- rearranged) non-small cell lung cancer (NSCLC) previously treated with crizotini b. Approximately 120 patients may be enrolled at approximately 50 sites in t he United States. Screening will occur over a 28-day period, after which eligibl e patients will initiate study treatment with alectinib. Study treatment will co ntinue until disease progression, unacceptable toxicity, withdrawal of consent, patient or physician decision to discontinue treatment, death, alectinib becomes commercially available in the United States following approval of alectinib by the FDA, or the Sponsor decides to close the trial, whichever occurs first.